1. Multivalent nanoparticles bind the retinal and choroidal vasculature.
- Author
-
Hennig R, Ohlmann A, Staffel J, Pollinger K, Haunberger A, Breunig M, Schweda F, Tamm ER, and Goepferich A
- Subjects
- Angiotensin II metabolism, Angiotensin II Type 1 Receptor Blockers administration & dosage, Angiotensin II Type 1 Receptor Blockers chemistry, Animals, Binding, Competitive, Calcium Signaling drug effects, HeLa Cells, Humans, Injections, Intravenous, Losartan administration & dosage, Losartan chemistry, Mice, Protein Binding, Receptor, Angiotensin, Type 1 drug effects, Surface Properties, Tissue Distribution, Angiotensin II Type 1 Receptor Blockers pharmacokinetics, Capillaries metabolism, Choroid blood supply, Drug Carriers, Losartan pharmacokinetics, Quantum Dots, Receptor, Angiotensin, Type 1 metabolism, Retinal Vessels metabolism
- Abstract
The angiotensin II receptor type 1 (AT1R), which is expressed in blood vessels of the posterior eye, is of paramount significance in the pathogenesis of severe ocular diseases such as diabetic retinopathy and age-related macular degeneration. However, small molecule angiotensin receptor blockers (ARBs) have not proven to be a significant therapeutic success. We report here on a nanoparticle system consisting of ARB molecules presented in a multivalent fashion on the surface of quantum dots (Qdots). As a result of the multivalent receptor binding, nanoparticles targeted cells with high AT1R expression and inhibited their angiotensin receptor signaling with an IC50 of 3.8 nM while showing only minor association to cells with low AT1R expression. After intravenous injection into the tail vein of mice, multivalent nanoparticles accumulated in retinal and choroidal blood vessels of the posterior eye. At the same time, multivalent ligand display doubled the Qdot concentration in the blood vessels compared to non-targeted Qdots. Remarkably, ARB-targeted Qdots showed no pronounced accumulation in AT1R-expressing off-target tissues such as the kidney. Following systemic application, this multivalent targeting approach has the potential to amplify AT1R blockade in the eye and concomitantly deliver a therapeutic payload into ocular lesions., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF